Tirzepatide may be better if you: Need a medication available right now : Tirzepatide is FDA-approved and available today through clinics and pharmacies Are sensitive to GI side effects : Lower overall side effect rates at every dose level Want established safety data : Years of post-marketing surveillance data available Have insurance coverage : Mounjaro/Zepbound may be partially covered Prefer a simpler titration : Uniform 2.5 mg steps are predictable and easy to follow Are a first-time incretin user : Extensive prescriber experience means better clinical support Retatrutide may be better if you: Have significant fatty liver disease : Liver fat reduction of up to 86% is unmatched Need maximum weight loss : 28.7% at 68 weeks exceeds all other compounds Have plateaued on tirzepatide : The glucagon component offers a new mechanism Are focused on metabolic health beyond weight : Triple agonism impacts more metabolic pathways Can tolerate higher GI burden : More side effects but more results Can wait for FDA approval : Expected late 2026-2027 for regulated access Neither compound is appropriate if you: Have a personal or family history of medullary thyroid carcinoma Have multiple endocrine neoplasia syndrome type 2 Are pregnant or planning pregnancy Have a history of severe psychiatric reactions to incretin therapies Have pancreatitis history (use with extreme caution) For researchers still undecided, the semaglutide vs tirzepatide comparison page provides additional context on how dual agonists compare to single agonists
Key Precursors and Enzymes Precursor molecules and key enzymes The synthesis of GSH depends on three precursor molecules: glutamate, cysteine and glycine, and this process is catalyzed by key enzymes
However, it is essential to consult with a qualified healthcare professional before incorporating BPC-157 into your daily routine, as they can provide personalized guidance based on your specific needs and circumstances
Am J Physiol Gastrointest Liver Physiol 281(3):G848G855
Functional analysis of gene expression was performed by using ranked DEGs (adjusted P 0.05) as input into Metacore (v.6.35)
No Current UK Marketing Authorisation Identified No current UK marketing authorisation for a BPC-157 plus TB-500 combination, BPC-157 or TB-500 was identified in the official sources reviewed for this article
